Skip to main content

Table 1 [A]: Descriptive characteristics of the patients included in the study; [B]: Linear regression model for the effect of various parameters in the upright RYAN score in the pre-defined cohort with 2-year follow-up

From: Laryngopharyngeal reflux in chronic obstructive pulmonary disease - a multi-centre study

[A]
Descriptive characteristics All patients
n = 193
Pre-defined cohort with 2-year follow-up
n = 107
Age (years), mean (SD) 66.2 (8.8) 67.5 (8.4)
BMI (kg/m2), mean (SD) 27.1 (6.7) 27.8 (6.6)
Medical history of GERD, n (%) 33 (17) 16 (15)
Treated with PPI, n (%) 69 (37) 33 (30.8)
Gender, male (%) 119 (62) 75 (70)
Smoking status, n (%)
 Current 62 (34) 38 (36)
 Past 121 (66) 69 (64)
GOLD Stage, n (%)
 I 25 (14) 6 (6)
 II 82 (45) 58 (58)
 III 55 (30) 32 (32)
 IV 21 (11) 4 (4)
COPD Medication
 LABA 55 (28) 19 (18)
 LABA+ICS 151 (78) 102 (96)
 LAMA 129 (67) 81 (76)
 SABA 26 (13) 2 (2)
 SAMA 39 (20) 35 (33)
Lung Function (post-BD), mean (SD)
 FEV1%predicted 56.9 (21.8) 57.4 (16.4)
 RV % predicted 144.3 (49.4) 136.6 (46.7)
 TLC %predicted 110.5 (20.5) 107.9 (20.5)
 DLCO% predicted 61.0 (22.8) 57.7 (18.5)
 FEV1/FVC 46.9 (14.1) 46.9 (13.1)
Questionnaire scores, mean (SD)
 GerdQ 2.1 (3.3) 2.1 (3.2)
 Leicester cough 96.5 (38.0) 104.6 (27.1)
 RSI 10.0 (9.2) 10.1 (8.4)
[B]
Parameter Pre-defined cohort with 2-year follow-up
(n = 107)
Beta 95% CI: Lower 95% CI: Upper p-value
Age 0.239 0.006 0.050 0.013
6MWT −0.073 −0.002 0.001 0.474
BODE Index 0.004 −0.099 0.103 0.969
Lung Function
 FEV1% predicted −0.010 −0.013 0.012 0.923
 TLC % predicted −0.182 −0.019 0.001 0.091
 RV % predicted −0.142 −0.007 0.001 0.177
Νumber of exacerbations during the study 0.015 −0.175 0.205 0.877
Number of severe exacerbations during the study −0.011 −0.305 0.272 0.911
Questionnaires
 GerdQ −0.257 −0.139 − 0.022 0.008
 Leicester cough 0.012 −0.007 0.008 0.899
 RSI −1.013 −0.034 0.011 0.314
  1. 95% CI 95% confidence interval, BMI body mass index, GERD gastroesophageal reflux disease, PPI proton pump inhibitors, GOLD Global Initiative for Chronic Obstructive Lung Disease, LABA long acting beta 2 agonist, LABA + ICS long-acting beta 2 agonist plus glucocorticosteroids, LAMA long-acting muscarinic antagonist, SABA short-acting beta 2 agonist, SAMA short-acting muscarinic antagonist, post-BD post-bronchodilator, FEV1 forced expiratory volume in 1 s, RV residual volume, TLC total lung capacity, DLCO diffusing capacity of the lung for carbon monoxide, GerdQ gastroesophageal reflux disease questionnaire, RSI Reflux symptom index, BODE Index Body mass, airflow obstruction, dyspnea and exercise capacity index, 6MWT 6-min walking test